OPKO Health (NASDAQ:OPK) Stock Price Breaks Below 50 Day Moving Average – Here’s What Happened

OPKO Health, Inc. (NASDAQ:OPK) shares crossed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $1.51 and traded as low as $1.32. OPKO Health shares last traded at $1.32, with a volume of 1,558,413 shares trading hands.

More OPKO Health News

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: Large cash infusion: Labcorp will pay approximately $722 million in cash, with total consideration potentially reaching $872 million subject to additional payments and transaction terms. The proceeds could strengthen OPKO’s balance sheet, support its drug-development programs and reduce reliance on external financing. OPKO Health stock soars on $722M BioReference asset sale
• Positive Sentiment: Strategic refocus: The divestiture enables OPKO to focus on its biopharmaceutical operations, including treatments and development programs, rather than continuing to operate a substantial laboratory-services business. Investors appear to be rewarding the clearer, more focused corporate strategy. Labcorp agrees to acquire BioReference assets
• Positive Sentiment: Valuable testing assets attract a strategic buyer: The transaction includes BioReference specialty testing businesses, such as women’s-health services and the 4Kscore blood test, which helps assess the likelihood of aggressive prostate cancer before biopsy decisions. Labcorp expects the deal to expand access to laboratory services nationwide. Labcorp to buy BioReference assets
• Neutral Sentiment: The agreement covers select BioReference assets rather than necessarily the entire business, and the maximum $872 million value includes contingent consideration. The final proceeds and timing therefore depend on closing conditions and deal mechanics. Labcorp buying select BioReference assets
• Negative Sentiment: After the sale, OPKO will lose revenue and operating contribution from the divested laboratory assets. Investors will likely focus on whether the cash proceeds and biopharma growth can offset the reduced scale of the diagnostics business.

Analysts Set New Price Targets

Several research analysts recently commented on OPK shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, August 13th. HC Wainwright restated a “buy” rating on shares of OPKO Health in a report on Wednesday, July 29th. Finally, Zacks Research raised OPKO Health from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, OPKO Health has a consensus rating of “Hold” and a consensus price target of $1.55.

OPKO Health Trading Up 17.5%

The company has a market capitalization of $1.20 billion, a PE ratio of -17.89 and a beta of 1.51. The company’s fifty day moving average is $1.52 and its 200-day moving average is $1.37. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.35 and a quick ratio of 2.93.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Monday, July 27th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.07. OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.88%. The company had revenue of $163.58 million during the quarter, compared to the consensus estimate of $131.23 million. During the same quarter in the previous year, the firm posted ($0.19) earnings per share. OPKO Health’s revenue for the quarter was up 4.3% compared to the same quarter last year. On average, analysts anticipate that OPKO Health, Inc. will post -0.23 EPS for the current fiscal year.

Institutional Trading of OPKO Health

Several hedge funds and other institutional investors have recently made changes to their positions in OPK. Squarepoint Ops LLC acquired a new stake in OPKO Health in the 2nd quarter worth approximately $62,000. Headlands Technologies LLC grew its position in OPKO Health by 91.2% during the 2nd quarter. Headlands Technologies LLC now owns 107,989 shares of the biotechnology company’s stock worth $162,000 after purchasing an additional 51,509 shares during the last quarter. Two Sigma Securities LLC acquired a new position in OPKO Health during the 2nd quarter valued at approximately $27,000. Van ECK Associates Corp increased its stake in OPKO Health by 174.0% during the 2nd quarter. Van ECK Associates Corp now owns 438,645 shares of the biotechnology company’s stock valued at $658,000 after purchasing an additional 278,549 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in OPKO Health during the 2nd quarter valued at approximately $1,194,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its diagnostics businesses, the company provides laboratory services and specialized tests intended to support the detection, diagnosis and management of disease. Its operations include BioReference Health, a clinical laboratory business serving physicians, hospitals, employers and patients, as well as the 4Kscore test, which helps assess the risk of aggressive prostate cancer.

OPKO’s pharmaceutical business develops and commercializes treatments for conditions including kidney disease, endocrine disorders and growth-related conditions.